Tedizolid phosphate is under clinical development by Merck and currently in Phase I for Gram-Positive Bacterial Infections. According to GlobalData, Phase I drugs for Gram-Positive Bacterial Infections have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tedizolid phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tedizolid phosphate overview
Tedizolid phosphate (TR-701, DA-7218, Sivextro) is a phosphate prodrug, is converted to tedizolid in the presence of phosphatases. It is formulated as injectable powder solution and concentrate solution for intravenous route of administration and tablets, coated tablets and film coated tablets for oral route of administration. Tedizolid phosphate is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), soft tissue infections (SSTI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, streptococcus agalactiae, streptococcus anginosus group (including streptococcus anginosus, streptococcus intermedius and streptococcus constellatus), and enterococccus faecalis.
See Also:
The drug candidate is under development for the treatment of acute bacterial skin and skin structure infections including cellulitis, erysipelas, major cutaneous abscess, wound infection and gram-positive infections. It was also under development for the treatment of ventilator associated bacterial Pneumonia (VABP) and hospital acquired bacterial Pneumonia (HABP), cellulitis, erysipelas, bacteremia and and skin and soft tissue infections (SSTI), complicated skin and skin structure infections and methicillin-resistant Staphylococcus aureus (MRSA) infections.
Merck overview
Merck is a biopharmaceutical company focused on the discovery, development, manufacturing and marketing of prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for therapy areas related to cardiovascular, cancer, immune disorders, infectious, respiratory, and diabetes. The company provides animal health products such as vaccines, poultry products, livestock products and aquaculture products. Merck sells medicines to drug wholesalers, retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company and its subsidiaries operate in the Americas, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.
For a complete picture of Tedizolid phosphate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
